Results 31 to 40 of about 20,714 (241)

Exocrine Pancreatic Insufficiency in Diabetes Mellitus: Incidence, Pathogenesis, Diagnosis and Treatment

Gastroenterologìa, 2015
The article deals with exocrine pancreatic insufficiency (EPI), which is being detected in a significant number (30–50 %) of patients with diabetes mellitus (DM) type I and II and could potentially affect the compensation of DM.
S.M. Tkach
doaj   +1 more source

Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer

Pharmacy
Most patients with pancreatic cancer at some point present with symptoms related to exocrine pancreatic insufficiency (EPI). These include diarrhea, abdominal bloating, indigestion, steatorrhea, weight loss, and anorexia.
Mary Acelle G. Garcia, Syed Imam, Ursula K. Braun, Leanne K. Jackson   +3 more
doaj   +1 more source

Pancreatic enzyme replacement therapy after gastric resection: An update [PDF]

Digestive and Liver Disease, 2018
Exocrine pancreatic insufficiency (EPI) is one of the possible mechanisms of fat maldigestion following gastric surgery, together with reduced food intake, loss of gastric reservoir, small bowel bacterial overgrowth and rapid small bowel transit. Oral pancreatic enzyme replacement therapy (PERT) is the mainstay of treatment for EPI.
Filippo, Antonini, Stefano, Crippa, Massimo, Falconi, Giampiero, Macarri, Raffaele, Pezzilli   +4 more
openaire   +2 more sources

COMPARING THE ENZYME REPLACEMENT THERAPY COST IN POST PANCREATECTOMY PATIENTS DUE TO PANCREATIC TUMOR AND CHRONIC PANCREATITIS

Arquivos de Gastroenterologia
Background - Among late postoperative complications of pancreatectomy are the exocrine and endocrine pancreatic insufficiencies. The presence of exocrine pancreatic insufficiency imposes, as standard treatment, pancreatic enzyme replacement.
Anna Victoria FRAGOSO, Martha Regina PEDROSO, Paulo HERMAN, André Luis MONTAGNINI   +3 more
doaj   +1 more source

Enzyme Replacement Therapy in the Pancreatic Duct Ligated Swine

Experimental Biology and Medicine, 1972
SummaryPancreatic duct ligation (PDL) in swine reduced absorption of dietary fat and protein to less than 50%. Supplementation of the diet with pancreatin 4X NF at 0.1, 0.5 and 1.0% resulted in a significant improvement in fat absorption which approached normal on the highest level of pancreatin.
A R, Imondi, R P, Stradley, R, Wolgemuth
openaire   +2 more sources

Neonatal diabetes mellitus – manifestation of GATA-6 syndrome [PDF]

Romanian Journal of Pediatrics
GATA6 syndrome is an unusual genetic disorder that presents complications during pregnancy, congenital heart defects, neonatal diabetes, and severe pancreatic dysfunction.
Galina Gorbunov, Andrian Chiriac, Marina Vasilita   +2 more
doaj   +1 more source

The heterodimeric amino acid transporters (HAT) of the SLC7/SLC3 family: A structure−function relationships and relevance to human pathology

FEBS Letters, EarlyView.
Heterodimeric amino acid transporters consist of SLC7 and SLC3 family proteins arranged in a conserved structural organization. They regulate nutrient transport across cell membranes, supporting essential cellular functions. These transporters also contribute to xenobiotic/drug uptake and distribution.
Mariafrancesca Scalise, Tiziano Mazza, Raffaella Scanga, Lara Console, Michele Galluccio, Cesare Indiveri   +5 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Pancreatic Enzyme Replacement Therapy: Not Only in Chronic Pancreatitis

Journal of Gastrointestinal and Liver Diseases
The therapeutic application of Pancrelipase spans several key gastroenterological conditions, ranging from chronic pancreatitis to genetic disorders such as cystic fibrosis. Consequently, pancreatic enzyme replacement therapy (PERT) is applicable in a variety of clinical settings, managing pancreatic insufficiency. Beyond chronic pancreatitis, PERT has
Mario, Capasso, Ludovica, Venezia, Filippo, Antonini, Luca, Barresi, Germana, De Nucci, Marco, Valvano   +5 more
openaire   +2 more sources

Pancreatic enzyme replacement therapy for young cystic fibrosis patients [PDF]

Journal of Cystic Fibrosis, 2009
Maldigestion in cystic fibrosis (CF) affects approximately 90% of patients. As soon as pancreatic insufficiency is identified, enzyme supplementation is prescribed even with breast fed infants. A pancreatic enzyme preparation developed particularly for infants, Creon for children (CfC), contains smaller granules to be administered with a dosing spoon ...
Munck, Anne, Duhamel, Jean-Francois, Lamireau, Thierry, Le Luyer, Bernard, Le Tallec, Claire, Bellon, Gabriel, Roussey, Michel, Foucaud, Pierre, Giniès, Jean Louis, Houzel, Anne, Marguet, Christophe, Guillot, Marcel, David, Valerie, Kapel, Nathalie, Dyard, François, Henniges, Friederike   +15 more
openaire   +2 more sources